Daniel Lynch, Director at Blueprint Medicines Corp (BPMC), sold 65,000 shares at $50.12 ($3.3M) on 2017-06-28, disclosed to the SEC on 2017-06-30.
Open-market sale of $3.3M BPMC by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.09 | 3,125 | $153K | 4.7% |
| 2 | $49.09 | 3,125 | $153K | 4.7% |
| 3 | $50.12 | 21,474 | $1.1M | 32.9% |
| 4 | $50.12 | 21,474 | $1.1M | 32.9% |
| 5 | $51.17 | 7,901 | $404K | 12.4% |
| 6 | $51.17 | 7,901 |
| $404K |
| 12.4% |
| Total | $50.28 avg | 65,000 | $3.3M | 100% |
| Filing → |
| SWTX | SELL | 2025-02-12 | $15.4M | — | Filing → |
| BPMC | SELL | 2018-02-16 | $1.0M | — | Filing → |
| BPMC | SELL | 2018-02-14 | $2.6M | — | Filing → |